Dmitry Balyasny Balyasny Asset Management
Dmitry Balyasny is the founder of Balyasny Asset Management, a major multi-strategy and multi-manager hedge fund platform. The firm allocates capital across fundamental equities, macro, quant, and other teams under a central risk framework. Balyasny’s platform is often cited alongside other leading pod-shop multi-strategy firms.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SPCX
SpaceX
SPCX
|
+$577M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$538M |
| 3 |
iShares Core S&P 500 ETF
IVV
|
+$517M |
| 4 |
Texas Instruments
TXN
|
+$413M |
| 5 |
Roku
ROKU
|
+$356M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
HOLX
Hologic
HOLX
|
+$357M |
| 2 |
Meta Platforms (Facebook)
META
|
+$326M |
| 3 |
Johnson Controls International
JCI
|
+$303M |
| 4 |
Applied Materials
AMAT
|
+$285M |
| 5 |
CTRA
Coterra Energy
CTRA
|
+$285M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 12.69% |
| 2 | Industrials | 9.96% |
| 3 | Consumer Discretionary | 8.03% |
| 4 | Healthcare | 7.46% |
| 5 | Financials | 6.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
FSUN
2176
FirstSun Capital Bancorp
FSUN
$1.76B
| $903K | ﹤0.01% |
23,293
-11,447
| -33% | -$419K |
|
2177
GCM Grosvenor
GCMG
$839M
| $901K | ﹤0.01% |
73,289
+52,434
| +251% | +$573K |
|
2178
PC Connection
CNXN
$1.97B
| $900K | ﹤0.01% |
+12,324
| New | +$822K |
|
2179
AutoNation
AN
$6.6B
| $899K | ﹤0.01% |
+4,838
| New | +$946K |
|
2180
Morgan Stanley Direct Lending Fund
MSDL
$1.29B
| $899K | ﹤0.01% |
59,442
-57,311
| -49% | -$868K |
|
2181
Vanguard Russell 2000 ETF
VTWO
$17.3B
| $899K | ﹤0.01% |
7,400
-2,000
| -21% | -$227K |
|
2182
CALL
Grab
GRAB
$14.2B
| $897K | ﹤0.01% |
238,000
| – | – |
|
2183
Brookfield
BN
$93.1B
| $896K | ﹤0.01% |
+21,000
| New | +$939K |
|
|
BMNR
2184
BitMine Immersion Technologies
BMNR
$13.8B
| $894K | ﹤0.01% |
+67,194
| New | +$1.3M |
|
2185
Dr. Reddy's Laboratories
RDY
$10.1B
| $894K | ﹤0.01% |
+61,707
| New | +$832K |
|
2186
PUT
Nucor
NUE
$55.3B
| $891K | ﹤0.01% |
+4,000
| New | +$905K |
|
2187
CALL
ProShares UltraPro QQQ
TQQQ
$35.7B
| $891K | ﹤0.01% |
+11,000
| New | +$764K |
|
2188
Myers Industries
MYE
$1.26B
| $890K | ﹤0.01% |
+25,209
| New | +$594K |
|
2189
Regenxbio
RGNX
$708M
| $887K | ﹤0.01% |
74,047
+62,391
| +535% | +$518K |
|
2190
PUT
Teva Pharmaceuticals
TEVA
$43.5B
| $884K | ﹤0.01% |
+26,100
| New | +$869K |
|
2191
CALL
Arista Networks
ANET
$238B
| $883K | ﹤0.01% |
5,200
-54,000
| -91% | -$8.48M |
|
2192
Prudential Financial
PRU
$41.8B
| $882K | ﹤0.01% |
8,172
+2,901
| +55% | +$295K |
|
2193
Shake Shack
SHAK
$3.06B
| $880K | ﹤0.01% |
15,704
-1,673,253
| -99% | -$126M |
|
2194
Energy Recovery
ERII
$403M
| $878K | ﹤0.01% |
97,386
+86,674
| +809% | +$824K |
|
2195
Liberty Media Series A
FWONA
$24.2B
| $876K | ﹤0.01% |
+10,008
| New | +$824K |
|
|
XZO
2196
Exzeo Group
XZO
$1.52B
| $871K | ﹤0.01% |
+51,638
| New | +$760K |
|
|
OKYO
2197
OKYO Pharma
OKYO
$80.8M
| $871K | ﹤0.01% |
580,596
-4,200
| -0.7% | -$6.73K |
|
|
SHAZ
2198
SharonAI Holdings
SHAZ
$2.11B
| $871K | ﹤0.01% |
+10,286
| New | +$580K |
|
2199
Adient
ADNT
$1.54B
| $869K | ﹤0.01% |
47,278
-370,574
| -89% | -$7.92M |
|
2200
Carlyle Secured Lending
CGBD
$781M
| $868K | ﹤0.01% |
82,388
+9,925
| +14% | +$111K |
|
Similar funds
Dmitry Balyasny's Q2 2026 Portfolio in Review
As of Q2 2026, Dmitry Balyasny held 3,665 positions worth $80.2B, up 4% from $77.1B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Dmitry Balyasny withdrew a net $7.14B in Q2 2026, closing 734 positions and reducing 995 holdings. Its most notable exit was Hologic, an estimated $357M position sold in full.
By sector, the portfolio is most concentrated in Technology at 13% of assets, up from 9.7% a quarter earlier, followed by Industrials and Consumer Discretionary.
Against the trend, Dmitry Balyasny opened a new position in SpaceX worth $581M.
- Dmitry Balyasny's largest Q2 2026 buy was SpaceX: 3,397,642 shares worth $581M.
- Dmitry Balyasny added most to State Street SPDR S&P 500 ETF Trust in Q2 2026, an estimated $538M increase.
- Dmitry Balyasny's biggest Q2 2026 reduction was Meta Platforms (Facebook), cutting an estimated $326M.
- Dmitry Balyasny fully exited Hologic in Q2 2026, selling an estimated $357M.
- Dmitry Balyasny's ten largest holdings make up 14% of its $80.2B portfolio in Q2 2026.
- Dmitry Balyasny opened 834 new positions and closed 734 in Q2 2026.
- Dmitry Balyasny's portfolio value rose 4% quarter-over-quarter to $80.2B.
Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.